Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tecfidera sales trounce estimates

Biogen Idec Inc. (NASDAQ:BIIB) reported $192.1 million in 2Q13 sales of newly launched multiple sclerosis drug Tecfidera dimethyl fumarate, more than double Street estimates of around $75

Read the full 275 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE